Published: March 2014
Read Executive Summary
Read Full-Text Document
This white paper offers guidance in the following three areas: 1) general safety and quality, including procedures; roles and qualification for the members of the brachytherapy team; source radionuclides, and types of reported medical events; 2) clinical applications for HDR brachytherapy by disease site, including intraluminal and intraoperative brachytherapy; and 3) key measures to avoid catastrophic failures.
Value of MRI without/with applicator in place for target definition in cervix cancer brachytherapy (CME)
Advancements in Clinical Brachytherapy (CME)
Podcast with document chair
ASTRO’s Brachytherapy Model Policy